- How to Spot, and Talk About, Hearing Loss in a Loved One
- Estrogen May Trigger Binge Drinking, Prelim Study Suggests
- The Number of Homeless People in the U.S. Has Increased
- Weight-Loss Drugs, Wily Viruses, Abortion Pill Under Attack: The Top Health Stories of 2024
- Use Your Freezer to Fight Food Waste, Protect the Planet
- Heat Waves Threaten Brain Health, Study Suggests
- Norovirus Cases Are Up in Pockets of the U.S.
- CDC Reports Potentially Troublesome Mutations in Bird Flu Found in Louisiana Patient
- Single Peoples’ Personalities Differ from Partnered Peoples’
- Singapore Is Ready for a Rapidly Aging Society, Study Says. What About the U.S.?
Donor-Lung Preservation Device Approved
The XVIVO Perfusion System has been approved by the U.S. Food and Drug Administration to help preserve donor lungs that ultimately may be used for transplant, the agency said Tuesday in a news release.
The device is expected to be used to preserve lungs that initially may not meet transplant criteria but could be used after doctors have been given more time to evaluate the organ, the agency said.
Transplant is an option for people with severe lung problems, such as chronic obstructive pulmonary disease (COPD), cystic fibrosis or idiopathic pulmonary fibrosis, the FDA said.
The just-approved device can be used to warm donor lungs to the appropriate temperature and flush lung tissue with a sterile solution called STEEN, the agency explained. The device also provides oxygen to the donor organ’s cells for up to four hours.
Device manufacturer XVIVO Perfusion, based in Englewood, Colo., will be required to conduct a post-approval study of the device’s long-term effects and any adverse reactions, the FDA said.
More information
Visit the FDA for more about this approval.
Source: HealthDay
Copyright © 2025 HealthDay. All rights reserved.